Olaparib Expanded, a phase II open-label, nonrandomized, investigator-initiated study, assessed Olaparib response in patients with metastatic BC with sBRCA1/2 mutations or another g/s mutation in homologous recombination-related genes, which are non-BRCA1/2. This evidence concerns the gene BRCA1 and breast cancer.